Tonix Pharmaceuticals has begun a significant clinical trial aimed at mitigating acute stress reactions in trauma survivors. The Phase 2 OASIS trial will evaluate TNX-102 SL's potential to reduce the severity of acute stress reaction and prevent the onset of acute stress disorder.
The study, sponsored by the University of North Carolina's Institute for Trauma Recovery and supported by a $3 million U.S. Department of Defense grant, will enroll approximately 180 motor vehicle trauma survivors across emergency departments nationwide. The trial builds upon previous research indicating TNX-102 SL's ability to improve sleep and early PTSD symptoms.
CEO Dr. Seth Lederman emphasized the critical nature of developing treatments for individuals experiencing traumatic events, highlighting potential applications in both civilian and military populations. The research addresses a significant gap in immediate psychological intervention following traumatic experiences.
Topline data from the trial is anticipated in the second half of 2026, potentially offering insights into new approaches for managing acute stress reactions. If successful, the study could provide a crucial medical intervention for individuals at risk of developing long-term psychological trauma.
